Business
Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting
LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March 08,
About this update from Lyell Immunopharma, Inc.
[{"type":"text","content":"LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, announced today that an abstract has been accepted for poster presentation at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, scheduled for April 8-13 in New Orleans. The poster presentation being presented at AACR will highlight the preclinical data characterizing LYL797, Lyell’s first therapeutic candidate incorporating T-cell reprogramming technologies for the treatment of solid tumors. LYL797 is an investigational chimeric antigen receptor (CAR) T-cell therapy for patients with receptor tyrosine kinase-like orphan receptor 1-positive (ROR1+) solid tumors. LYL797 incorporates two Lyell technologies designed to address major barriers to successful Adoptive Cell Therapy (ACT): Gen-R™, a genetic reprogramming technology that endows T cells with the ability to resist exhaustion, and Epi-R™, an epigenetic reprogramming technology that creates populations of T cells with the properties of durable stemness. T cells with properties of durable stemness are able to proliferate, persist, and self-renew with anti-tumor functionality. “With LYL797 entering clinical development, we are excited to present the preclinical data evaluating our two T-cell reprogramming technologies which are designed to overcome the barriers we believe have impeded the development of more effective cell therapies for patients with solid tumor cancers,” said Tina Albertson, MD, PhD, Chief Medical Officer and Head of Development of Lyell. “Reprogramming T cells to be able to resist exhaustion and demonstrate properties of durable stemness is key to our mission to develop cell therapies that can outlast and eradicate hard-to-kill solid tumors.” Details on the poster presentation are below: Poster Title: LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumorsSession: Adoptive Cell TherapyAbstract Number: 3808Presentation Date, Time & Location: Tuesday, April 12, 9:00am – 12:30pm, Section 30Presenter: Spencer Park, PhD, Lyell Immunopharma The abstract has been posted t...